1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,319 | 0,359 | 07:28 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | Sprint Bioscience AB: Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication | 149 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces the conclusion of a targeted evaluation of the STK25 program, conducted in partnership with the Experimental Drug Development Centre (EDDC), Singapore's national... ► Artikel lesen | |
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 01.04. | Sprint Bioscience AB: Sprint Bioscience appoints Jenni Björnulfson as CFO | 140 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces that Jenni Björnulfson has been appointed chief Financial Officer (CFO) of the company. With extensive and diverse experience in both life science and finance... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Positive results expand the NNMT program into Chronic Kidney Disease | 130 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from its NNMT program from a proof-of-concept study demonstrating therapeutic potential in Chronic Kidney Disease (CKD). Based on these findings... ► Artikel lesen | |
| 17.03. | Sprint Bioscience AB: Sprint Bioscience reports positive results from the VRK1 program | 171 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from a pre-clinical proof-of-concept (POC) study performed within the company's VRK1 program. The results show that VRK1 inhibition selectively... ► Artikel lesen | |
| 24.11.25 | Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences | 839 | AFX News | FOSTER CITY (dpa-AFX) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 19,330 | -1,88 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,360 | 0,00 % | COSCIENS Biopharma Inc. GAAP EPS of -$0.06, revenue of $1.9M | ||
| HALOZYME THERAPEUTICS | 61,40 | +1,66 % | Halozyme Therapeutics, Inc.: Halozyme Reports First Quarter 2026 Results And Reiterates 2026 Financial Guidance | Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in 2026
Total Revenue Increased 42% YOY to $377 millionRoyalty Revenue... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 4,165 | -1,19 % | AbCellera-Aktie vor Zahlen - setzt sich die Rallye weiter fort? | Die AbCellera-Aktie ist am vergangenen Freitag um rund +9% gestiegen und legte nachbörslich nochmals um weitere knapp +5% zu. Damit rücken die heutigen Quartalszahlen zunehmend in den Fokus, da der... ► Artikel lesen | |
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Expands Distribution with Two of Canada's Largest Cannabis Retailers, Launches New Product Innovation and Advances National Growth Strategy | Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting continued... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 206,00 | -0,10 % | Bio-Rad Laboratories Swings To Q4 Profit | WASHINGTON (dpa-AFX) - Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025.... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Kerri McCullough Wood as Chief Commercial Officer | Experienced life sciences leader to drive global commercial strategy and accelerate growth across early- and late-phase biologics programsTUSTIN, Calif., May 11, 2026 /PRNewswire/ -- Avid... ► Artikel lesen | |
| BIOLINERX | 2,280 | -3,39 % | BioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer CenterData... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,120 | 0,00 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026
Cash, cash equivalents and short-term investments balance... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 5,080 | +6,99 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates | Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened
Previous open label trial data presented at SIRS 2026 showed no safety or drug-drug... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,340 | -4,10 % | Ovid Therapeutics: Aktie steigt nach erwartungsgemäßen Ergebnissen und Pipeline-Fortschritten | ||
| COCRYSTAL | 1,110 | -0,89 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus | Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,077 | 0,00 % | Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics | Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 6,920 | -1,00 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B
Precision... ► Artikel lesen |
SPRINT BIOSCIENCE AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.